Compare NWSA & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWSA | MEDP |
|---|---|---|
| Founded | 2012 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6B | 16.6B |
| IPO Year | 2012 | 2016 |
| Metric | NWSA | MEDP |
|---|---|---|
| Price | $30.35 | $617.10 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 12 |
| Target Price | $38.18 | ★ $473.17 |
| AVG Volume (30 Days) | ★ 3.3M | 175.5K |
| Earning Date | 05-07-2026 | 04-22-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | N/A | ★ 20.98 |
| EPS | 1.03 | ★ 8.53 |
| Revenue | ★ $9,028,000,000.00 | N/A |
| Revenue This Year | $6.06 | $13.19 |
| Revenue Next Year | $3.25 | $7.75 |
| P/E Ratio | ★ $29.55 | $72.74 |
| Revenue Growth | ★ 6.81 | N/A |
| 52 Week Low | $22.20 | $373.00 |
| 52 Week High | $31.66 | $677.90 |
| Indicator | NWSA | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 63.36 |
| Support Level | $25.78 | $561.82 |
| Resistance Level | $30.88 | $629.30 |
| Average True Range (ATR) | 0.61 | 13.67 |
| MACD | -0.14 | -0.97 |
| Stochastic Oscillator | 52.70 | 90.48 |
News Corporation is a diversified media and information services conglomerate with significant presence in the US, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings platform in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable US digital property advertising business, Move. The 65% interest in Foxtel, the Australian pay-TV and streaming provider, was sold in April 2025. The sale to global sports streaming platform, DAZN, was struck at more than 7 times Foxtel's EBITDA.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.